Springworks Therapeutics, INC Form 4 insider transactions
Director Daniel Lynch sold shares of SpringWorks Therapeutics (SWTX) common stock on February 10, 2025, under a pre-arranged trading plan.
SpringWorks Therapeutics CEO Saqib Islam sold 48,000 shares of common stock on February 10, 2025, at a weighted average price of $53.2966 per share, according to a Form 4 filing with the SEC.
Director Julie Hambleton exercised stock options and sold shares of SpringWorks Therapeutics (SWTX) on February 10, 2025, according to a Form 4 filing with the SEC.
Badreddin Edris, Chief Operating Officer of SpringWorks Therapeutics, sold 30,000 shares of common stock at an average price of $53.1265 on February 10, 2025, according to a Form 4 filing with the SEC.
Herschel Weinstein, General Counsel & Secretary of SpringWorks Therapeutics, received grants of restricted stock units and stock options on January 10, 2025.
Daniel Pichl, Chief People Officer at SpringWorks Therapeutics, received grants of restricted stock units and stock options on January 10, 2025.
Form 4: SpringWorks Therapeutics CFO Francis Perier Jr. Receives Stock Options and Restricted Stock Units
Francis Perier Jr., CFO of SpringWorks Therapeutics, was granted stock options and restricted stock units on January 10, 2025, according to a recent SEC Form 4 filing.
Michael Nofi, Chief Accounting Officer of SpringWorks Therapeutics, received grants of restricted stock units and stock options on January 10, 2025.
Form 4: SpringWorks Therapeutics Chief Scientific Officer Receives Stock Options and Restricted Stock Units
SpringWorks Therapeutics' Chief Scientific Officer, Tai-An Lin, was granted stock options and restricted stock units on January 10, 2025.
SpringWorks Therapeutics CEO, Saqib Islam, was granted stock options and restricted stock units on January 10, 2025, according to a recent SEC filing.
SpringWorks Therapeutics' Chief Operating Officer, Badreddin Edris, was granted stock options and restricted stock units on January 10, 2025.
James Cassidy, Chief Medical Officer of SpringWorks Therapeutics, reports the acquisition of stock options and restricted stock units.
Bhavesh Ashar, Chief Commercial Officer of SpringWorks Therapeutics, reports the acquisition of restricted stock units and stock options.
A SpringWorks Therapeutics executive, Bhavesh Ashar, disposed of shares to cover tax obligations related to vesting restricted stock units.
Form 4: SpringWorks Therapeutics Executive Herschel S. Weinstein Disposes of Shares to Cover Tax Obligations
Herschel S. Weinstein, General Counsel & Secretary at SpringWorks Therapeutics, disposed of shares to cover tax obligations related to vesting restricted stock units.
A SpringWorks Therapeutics executive, Daniel Pichl, sold shares to cover tax obligations related to vesting restricted stock units.
SpringWorks Therapeutics' Chief Financial Officer, Francis I. Perier Jr., reported the withholding of company stock to cover tax obligations related to vesting restricted stock units.
Michael Nofi, Chief Accounting Officer at SpringWorks Therapeutics, reported the withholding of shares to cover tax obligations related to vesting restricted stock units.
SpringWorks Therapeutics' Chief Scientific Officer, Tai-An Lin, disposed of 855 shares to cover tax obligations related to vesting restricted stock units.
SpringWorks Therapeutics CEO, Saqib Islam, disposed of shares to cover tax obligations related to vesting restricted stock units.
SpringWorks Therapeutics' Chief Operating Officer, Badreddin Edris, disposed of shares to cover tax obligations related to vesting restricted stock units.
SpringWorks Therapeutics' Chief Medical Officer, James Cassidy, disposed of company stock to cover tax obligations related to vesting restricted stock units.
SpringWorks Therapeutics' Chief Operating Officer, Badreddin Edris, sold a total of 20,000 shares of common stock on December 3, 2024, under a pre-arranged 10b5-1 trading plan.
SpringWorks Therapeutics CEO, Saqib Islam, sold a total of 49,000 shares of common stock on December 2, 2024, under a pre-arranged 10b5-1 trading plan.
Tai-An Lin, Chief Scientific Officer of SpringWorks Therapeutics, disposed of 2,324 shares of common stock on October 2, 2024, to cover tax withholding obligations related to vesting restricted stock units.
SpringWorks Therapeutics CEO Saqib Islam sold a portion of his holdings in the company's common stock on September 3, 2024, under a pre-arranged trading plan.
Edris Badreddin, Chief Operating Officer of SpringWorks Therapeutics, sold a total of 19,920 shares of common stock in multiple transactions on September 3, 2024, under a pre-arranged trading plan.
Chief Medical Officer James Cassidy of SpringWorks Therapeutics reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.
Martin Mackay, a director at SpringWorks Therapeutics, received initial equity grants consisting of restricted stock units and stock options as part of the company's non-employee director compensation policy.
James Cassidy, Chief Medical Officer of SpringWorks Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.